Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Ascentage Pharma Group International ( (HK:6855) ) is now available.
Ascentage Pharma Group International announced the further grant of awards under its 2022 RSU Scheme, allocating 1,304,457 RSUs to 146 selected individuals, including directors and service providers. This move is part of the company’s strategy to incentivize its team and align their interests with long-term growth objectives, potentially enhancing its competitive positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:6855) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing novel therapies for cancer, hepatitis B, and age-related diseases. The company is known for its research and development efforts in drug development and clinical trials, aiming to address unmet medical needs in these areas.
Average Trading Volume: 2,389,582
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.46B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.